Aura Biosciences Stock

aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Aura Biosciences before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Aura Biosciences Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Aura Biosciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/22/2021 Series E $80.48MM $xx.xx $283.03MM Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
102,671,041
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Adage Capital Management Lp, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures, Matrix Capital Management, Medicxi, Rock Springs Capital, Surveyor Capital, Velosity Capital, Ysios Capital
07/09/2020 Series D-2 $17MM $xx.xx $157.27MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
24,598,481
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
04/02/2019 Series D-1 $40MM $xx.xx $139.53MM Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
57,878,742
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Medicxi, Ysios Capital
12/21/2017 Series C-2 $12.12MM $xx.xx $73.09MM Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
33,218,192
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
12/21/2017 Series C-1 $30.29MM $xx.xx $73.09MM Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
58,109,711
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Li-Cor Biosciences, Lundbeckfonden Ventures, Ysios Capital
03/05/2015 Series B $28.21MM $xx.xx $50.26MM Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital
Price per Share
$xx.xx
Shares Outstanding
22,705,646
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Li-Cor Biosciences, Ysios Capital
08/17/2014 Series A-2 $5.37MM $xx.xx $22.08MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,325,021
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
07/04/2013 Series A-1 $8.2MM $xx.xx $29.11MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,298,732
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/26/2011 Series A $3.4MM $xx.xx $16MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,701,141
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Leadership & Board

Leadership

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Richard Peters Ph.D
Advisor
Andrew Russell Ph.D
Director, Manufacturing
Stephen Monks Ph.D
Senior Vice President, Development
Alan Walts Ph.D
Executive Chairman
Julie Feder
Chief Financial Officer
Cadmus Rich MD
Chief Medical Officer
Michele Keough
Senior Vice President, R&D Operations

Board

Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Casper Breum
Lundbeckfonden
Henri Termeer
Javier García
Columbus Venture Partners
Rajesh Parekh Ph.D
Advent Life Sciences
Arthur Pappas
Chiesi Ventures
Giovanni Mariggi Ph.D
Medicxi
Joël Jean-Mairet Ph.D
Ysios Capital
Salvador Garcia-Atance Ph.D
Israel Ruiz
Alan Walts Ph.D
Mark Chin
Arix Bioscience

Aura Biosciences stock FAQs

plusminus

Can you buy Aura Biosciences stock?

You can no longer buy Aura Biosciences stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Aura Biosciences stock?

You can no longer buy Aura Biosciences stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Aura Biosciences stock?

You can no longer sell stock of Aura Biosciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Aura Biosciences stock?

You can no longer sell stock of Aura Biosciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Aura Biosciences a public company?

Aura Biosciences is now a public company traded on NASDAQ with ticker AURA.
plusminus

What is Aura Biosciences’ stock price?

The stock price of Aura Biosciences is $7.74 as of 1/18/24.
plusminus

What is Aura Biosciences’ stock ticker symbol?

The ticker symbol of Aura Biosciences is AURA.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Aura Biosciences News and Media Highlights

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum
Browse Insights
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.